Education
About Us
Working with TipRanks
Follow Us
Roy D. Baynes Insider Profile
4 Followers
Roy D. Baynes, Director at Travere Therapeutics, holds 18.43K shares in Natera (Ticker: NTRA), holds 37.50K shares in Travere Therapeutics (Ticker: TVTX), holds 43.50K shares in Atara Biotherapeutics (Ticker: ATRA).
Roy D. Baynes has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Roy D. Baynes holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Roy D. Baynes
Roy D. Baynes's Trading History
Travere Therapeutics
May 16, 2025
Director
Uninformative Buy
―
$1.12M
Atara Biotherapeutics
Jun 27, 2022
Director
Uninformative Buy
―
$235.77K
Natera
Feb 03, 2026
Director
Uninformative Buy
―
$3.83M
Nurix Therapeutics
―
Director
―
―
Aardvark Therapeutics, Inc.
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Roy D. Baynes's performance on stock
You May Also Like
Roy D. Baynes insider profile FAQ
What is the percentage of profitable transactions made by Roy D. Baynes?
The percentage of profitable transactions made by Roy D. Baynes is ―.
What is the average return per transaction made by Roy D. Baynes?
The average return per transaction made by Roy D. Baynes is ―.
What stocks does Roy D. Baynes hold?
Roy D. Baynes holds: TVTX, ATRA, NTRA, NRIX, AARD stocks.
What was Roy D. Baynes’s latest transaction?
Roy D. Baynes latest transaction was an Uninformative Buy of ―.
What was Roy D. Baynes's most profitable transaction?
Roy D. Baynes’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Roy D. Baynes's role in Travere Therapeutics?
Roy D. Baynes's role in Travere Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.